Trial Profile
A phase 3 study of mifepristone in patients with triple-negative breast cancer.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 May 2015
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- 18 May 2015 New trial record
- 13 May 2015 According to Corcept Therapeutics media release, company is planning to initiate this trial in early 2016.